Table 1.

Summary of patient characteristics and HSP-70 results

RF ablation patient group			Liver biopsy patient group
Patients	n = 22		Patients	n = 20
Male	n = 16		Male	n = 13
Female	n = 6		Female	n = 7
Mean agea	63 years (range: 28–81 years)	p = 0.002	Mean agea	50 years (range: 20–70 years)
RF ablations	n = 32 (1–3 sessions per patient)
1 session	n = 13
2 sessions	n = 8
3 sessions	n = 1
Treated organ			Biopsy organ
Liver	n = 18		Liver	n = 20
Kidney	n = 2
Lung	n = 1
Lung and liver	n = 1
Primary diagnosisb			Primary diagnosisb
CRC	n = 12		Chronic viral hepatitis	n = 6
HCC	n = 4		HCC	n = 6
RCC	n = 2		Hepatic metastases	n = 2
CCC	n = 1		PBC	n = 2
NCP	n = 1		PSC	n = 1
AGC	n = 1		Steatohepatitis	n = 1
CM	n = 1		Ethylic liver cirrhosis	n = 1
			Graft rejection after LTX	n = 1
HSP-70			HSP-70
Mean HSP-70 serum pre-RF (day 0)	4.6 ng/ml		Mean HSP-70 serum pre-biopsy (day 0)	<1.0 ng/ml
	SD 3.0
Mean HSP-70 serum post-RF (day 1)	7.3 ng/ml	p = 0.001	Mean HSP-70 serum post-biopsy (day 1)	<1.0 ng/ml
	SD 4.6
Mean HSP-70 serum first follow-up post-RF	3.4 ng/ml	p = 0.004
	SD 2.0

^aAge at first RF ablation or at biopsy

^bCRC colorectal carcinoma, HCC hepatocellular carcinoma, RCC renal cell carcinoma, CCC cholangiocellular carcinoma, NCP neuroendocrineous carcinoma of the pancreas, AGC adrenal gland carcinoma, CM choroidal melanoma, PSC primary sclerosing cholangitis, PBC primary biliary cirrhosis, LTX liver transplantation